In recent decades, cancer incidence and mortality rates have been increasing both in Russia and worldwide. According to the WHO, cancer is the second leading cause of death in the world. By 2040, the number of cancer deaths is projected to reach 16.4 million.

Oncological diseases affect men and women of different ages, but a particularly high incidence rate is observed among people aged 60-80.

Russia is among the TOP 10 countries in terms of the number of cancer cases and deaths. The increase in the number of the disease cases is due not only to an aging population, but also to improved diagnostics that helps detect cancer at earlier stages.

The increase in morbidity also affects the expansion of the market of oncological drugs. In 2022, sales of such drugs in Russia amounted to 257 billion rubles and about 22 million packages. The market shows a high growth rate. For example, the increase over 5 years was +33% in value terms and +11% in physical terms.

The Pharmasyntez Group of Companies is a major player in the market of oncological drugs. Since 2015, the company has been actively developing its work in the field of oncology at its site "Pharmasyntez-Nord". Currently, the company's product portfolio includes more than 45 cytostatic drugs, 99% out of which are included in the List of Vital and Essential Drugs of the Ministry of Health of the Russian Federation.

For the eighth consecutive year, the Pharmasyntez Group of Companies is a partner of the International Oncology Forum White Nights.

This year, the Pharmasyntez-Nord team presented a pipeline of 43 antineoplastic drugs. The products aroused great interest in the medical community. At the company's exhibition stand, representatives spoke with oncologists about new drugs and the company's research base. The forum became a platform for exchanging experiences and establishing further cooperation.